NIROGACESTAT

USDailyMed:Nirogacestat L01XX81(WHO) US:℞-onlyEU:Rx-only (S)-2-((S)-5,7-Difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide 1290543-63-3Hydrobromide:1962925-29-6 46224413 347828323 7746 DB12005 26232306 QZ62892OFJHydrobromide:9T1XY6L45Y D10960Hydrobromide:D11453 CHEBI:229217 ChEMBL1770916 O6U (PDBe,RCSB PDB) DTXS‍‍‍‍‍‍​​​‍​​​​​​ID60235679 Interactive image CCC[C@@](N[C@@]1([H])CCC2=CC(F)=CC(F)=C2C1)([H])/C(O)=N/C3=CN(C(C)(CNCC(C)(C)C)C)C=N3 InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)/t20-,23-/m0/s1Key:VFCRKLWBYMDAED-REWPJTCUSA-N Nirogacestat, sold under the brand nameOgsiveo, is ananti-cancer medicationused for the treatment ofdesmoid tumors.It is a selectivegamma secretaseinhibitorthat is takenby mouth. Nirogacestat was approved for medical use in the United States in November 2023.It is the first medication approved by the USFood and Drug Administration(FDA) for the treatment of desmoid tumors.The FDA considers it to be afirst-in-class medication.